Compare Eli Lilly And Co (LLY) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Microchip Technology Inc. — how do they compare? Eli Lilly And Co trades at $1,221.24 (market cap $1.08T), while Microchip Technology Inc. trades at $80.33 (market cap $43.99B). The key difference: Eli Lilly And Co is far larger — about 24.6× Microchip Technology Inc.'s market cap, and Microchip Technology Inc. pays the higher dividend (2.25%). Which is the better fit depends on your goals.
| LLY | MCHP | |
|---|---|---|
Market Cap | $1.08T | $43.99B |
Sector | Health | Technology |
52-Week High | $1.24K | $102.97 |
52-Week Low | $639.43 | $49.02 |
Enterprise Value | $1.13T | $49.12B |
Dividend Yield | 0.57% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Microchip Technology (MCHP) trades at $80.45, down 1.15% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats, including Q1 2026 EPS of $0.57 versus $0.505 expected (Zacks Investment Research, 2026-08-07), highlight robust demand recovery and data center growth. The company maintains solid profitability with a 60.19% gross margin but faces high valuation multiples like a P/E of 119.15.
The outlook is positive driven by AI and data center expansion, with a consensus price target of $104.00 (MarketBeat, 2026-08-07). Risks include elevated debt levels and sensitivity to semiconductor cycles. Upside potential exists if execution continues to exceed expectations amid broadening demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
